Staying in the Lead

Program Overview

Join us for an engaging CME COMPETE™ activity where education meets competition! This program offers an interactive, case-based format designed to deepen clinician knowledge and application of management strategies in sickle cell disease (SCD). Participants will explore the complexities of the patient journey while evaluating evidence surrounding current and emerging therapies, including novel targeted pyruvate kinase (PK) activators. Faculty experts will facilitate discussions on guideline-directed management, treatment selection, and transitions of care, challenging attendees to apply clinical data in key decision-making areas. Through this structured competition, learners will enhance their ability to individualize therapy and optimize outcomes for patients across the continuum of SCD care.

Target Audience

The educational design of this activity addresses the needs of adult and pediatric hematologists, pediatricians, and internal/family medicine MDs, NPs, PAs, and nurses who care for patients with SCD.

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe the underlying pathophysiology of sickle cell disease (SCD), including the mechanistic rationale behind the development of novel therapies
• Discuss clinical profiles of novel FDA-approved and emerging therapeutic approaches for SCD, with a focus on pyruvate kinase activators
• Individualize treatment strategies for patients with SCD that reflect current clinical practice guidelines and incorporate FDA-approved therapies
• Implement patient-centered management approaches that include shared decision-making, effective patient and caregiver education, and evidence-based transition of care practices

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Lakiea Bailey, PhD: Nothing to disclose.

Modupe Idowu, MD: Consulting Fees: Fulcrum Therapeutics, Pfizer, Inc.; Contracted Research: Agios Pharmaceuticals, Inc., Fulcrum Therapeutics, Novartis, Novo Nordisk Inc., Pfizer, Inc.

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.